PharmVar GeneFocus: CYP2D6

C Nofziger, AJ Turner, K Sangkuhl… - Clinical …, 2020 - Wiley Online Library
The Pharmacogene Variation Consortium (PharmVar) provides nomenclature for the highly
polymorphic human CYP2D6 gene locus. CYP2D6 genetic variation impacts the metabolism …

Complexities of CYP2D6 gene analysis and interpretation

A Gaedigk - International review of psychiatry, 2013 - Taylor & Francis
Abstract Cytochrome P450 2D6 (CYP2D6) plays an important role in the metabolism and
bioactivation of about 25% of clinically used drugs including many antidepressants …

Therapeutics data commons: Machine learning datasets and tasks for drug discovery and development

K Huang, T Fu, W Gao, Y Zhao, Y Roohani… - arXiv preprint arXiv …, 2021 - arxiv.org
Therapeutics machine learning is an emerging field with incredible opportunities for
innovatiaon and impact. However, advancement in this field requires formulation of …

Beyond generative models: superfast traversal, optimization, novelty, exploration and discovery (STONED) algorithm for molecules using SELFIES

AK Nigam, R Pollice, M Krenn… - Chemical …, 2021 - pubs.rsc.org
Inverse design allows the generation of molecules with desirable physical quantities using
property optimization. Deep generative models have recently been applied to tackle inverse …

Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations

A LLerena, MEG Naranjo… - Expert opinion on …, 2014 - Taylor & Francis
Introduction: The frequency of CYP2D6 alleles, related to either a lack of or increased
enzymatic activity, which may lead to poor metabolism (PM) or ultrarapid metabolism (UM) …

Determinants of approved acetylcholinesterase inhibitor response outcomes in Alzheimer's disease: relevance for precision medicine in neurodegenerative diseases

S Lista, A Vergallo, SJ Teipel, P Lemercier… - Ageing research …, 2023 - Elsevier
Acetylcholinesterase inhibitors (ChEI) are the global standard of care for the symptomatic
treatment of Alzheimer's disease (AD) and show significant positive effects in …

Drug metabolism in preclinical drug development: a survey of the discovery process, toxicology, and computational tools

NT Issa, H Wathieu, A Ojo, SW Byers… - Current drug …, 2017 - ingentaconnect.com
Background: While establishing efficacy in translational models and humans through
clinically-relevant endpoints for disease is of great interest, assessing the potential toxicity of …

[PDF][PDF] Proteome‐wide analyses of human hepatocytes during differentiation and dedifferentiation

C Rowe, DT Gerrard, R Jenkins, A Berry, K Durkin… - …, 2013 - Wiley Online Library
Failure to predict hepatotoxic drugs in preclinical testing makes it imperative to develop
better liver models with a stable phenotype in culture. Stem cell‐derived models offer …

[HTML][HTML] DeamiDATE 1.0: Site-specific deamidation as a tool to assess authenticity of members of ancient proteomes

A Ramsøe, V van Heekeren, P Ponce, R Fischer… - Journal of …, 2020 - Elsevier
Contamination is a potential problem in the study of ancient proteins, either from prior
handling of the sample, laboratory consumables, or cross-sample carryover from mass …

Atomoxetine: a review of its pharmacokinetics and pharmacogenomics relative to drug disposition

G Yu, GF Li, JS Markowitz - Journal of child and adolescent …, 2016 - liebertpub.com
Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor approved for the treatment
of attention-deficit/hyperactivity disorder (ADHD) in children (≥ 6 years of age), adolescents …